ESTRO 2024 - Abstract Book

S302

Brachytherapy - Head & neck, skin, eye

ESTRO 2024

PRESCRIPTION: The dose at point A (located in the middle of both plastic tubes) corresponds to 100% of the dose. The prescription is at 85% of the isodose curve.

DOSE & FRACTIONATION: 9-10 fractions of 3.5-4 Gy twice a day during hospitalization in 5-8 days. The most frequent scheme is 4 Gy x 10 fractions when the tumor is present or 9 if it is postoperative.

During the treatment fraction, a lead shielding is placed to protect the eyeball, lens, and upper eyelid.

Results:

Follow up was performed the first month after the treatment, then every 6 months for up to a pair of years and then once a year for 5 years. The last control was carried out in October 2023, the patients completed a questionnaire through a phone call, none of them reported any relevant secondary effects except for the loss of eyelashes.

Patients described slight dryness of the eye, however this secondary effect did not affect their daily life. No cataracts, ectropion, epiphora, or cosmetic alterations were reported. No relapse has happened.

Conclusion:

HDR brachytherapy of the eyelid is a well-tolerated alternative to surgery with good cosmetic results and minor functional alteration. Due to the low incidence of this malignancy the experience is limited, but the results from our center do not show relapses and only loss of eyelashes and slight eye dryness as secondary effects, none of them interfering with daily life.

Keywords: COSMETIC, LOCAL, INTERVENTION

1537

Digital Poster

Brachytherapy efficacy and safety in the treatment of primitive tongue carcinomas

Abel Cordoba 1 , Aziliz Dreszer 2 , Cecile Olejnik 2 , Estelle Aymes 3 , Alexandre Escande 1 , Sophie El Bedoui 4 , Samia Bouhir 4 , Bernard Coche 1 , Xavier Mirabel 1 , Eric F Lartigau 1 , Mael Barthoulot 3 , Xavier Liem 1 1 Oscar Lambret Center, Department of Radiation oncology and Brachytherapy, Lille, France. 2 CHU, Department of Odontology, Lille, France. 3 Oscar Lambret Center, Department of Biostatistics, Lille, France. 4 Oscar Lambret Center, Department of Otorhinolaryngology, Lille, France

Purpose/Objective:

The aim of this study was to evaluate the efficacy and safety of brachytherapy for the treatment of early stage tongue carcinoma and identify factors associated with the risk of local recurrence. The interest is to discuss the contribution of brachytherapy among therapeutics of tongue tumors treatments.